Fluorobenzofuran Composition for Fast-Acting CNS Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mental disorders such as PTSD, depression, and anxiety disorders are slow to produce therapeutic effects and often have undesirable side effects, including high abuse liability and toxicity, necessitating the development of faster-acting and safer therapeutic alternatives.
Innovation Solution
Development of halogenated benzofuran compounds, particularly fluorobenzofurans, that act as selective serotonin and dopamine modulators, providing rapid therapeutic effects and reducing adverse reactions, with enhanced binding affinity to specific receptors like 5-HT2C.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current medications for mental disorders are used, then therapeutic effects are achieved, but the treatment takes weeks or more to show results and patients may stop medication due to impatience or perceived lack of effectiveness
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of benzofuran compounds through halogen substitution (fluorine, chlorine, or bromine atoms at specific positions). This structural parameter change results in compounds with optimized pharmacokinetic properties, including faster onset of action and improved bioavailability, thereby reducing the ramp-up time while maintaining therapeutic effectiveness
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecular structures that combine benzofuran core with halogen substituents and various functional groups (amino, hydroxyl, alkoxy). These composite structures achieve multiple therapeutic effects simultaneously, including faster action and reduced side effects, resolving the contradiction between speed and effectiveness
2Reliability
If current medications for mental disorders are used, then therapeutic effects are achieved, but undesirable side effects including high abuse liability and toxicity occur
Solution Approach 1:
The patent applies local quality by introducing halogen atoms at specific positions (4, 5, 6, or 7) on the benzofuran ring structure. This localized modification at specific sites alters the compound's interaction with neurotransmitter systems, reducing abuse liability and toxicity while preserving the desired therapeutic effects on serotonin and dopamine systems
Solution Approach 2:
The patent converts the potentially harmful property of halogen substitution (which can increase toxicity) into a benefit by carefully selecting fluorine, chlorine, or bromine at specific positions. This transforms what could be a harmful modification into one that enhances therapeutic profile by reducing abuse liability and cardiovascular risks while maintaining effectiveness
3Speed
If halogenated benzofuran compounds are developed with enhanced binding affinity to specific receptors, then rapid therapeutic effects are achieved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular design into distinct modular components: a benzofuran core structure, halogen substituent options, and various functional group attachments. This modular approach allows systematic optimization of binding affinity and onset speed while managing complexity through standardized building blocks that can be combined in predictable ways
Data Source
AI summary
The present invention discloses pharmaceutically active halogenated benzofuran compounds, for example fluorobenzofurans for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes fluorobenzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.